In addition, direct targeting of cytokines such as IL-6, which is already being targeted clinically with agents like tocilizumab, could potentially be explored in combination with BET inhibitor to further suppress tumor-promoting inflammation (102, 103). The gene discussed is IL6; the disease is neoplasm.